Join Aitia at the GAP-Net Site Optimization Conference in New Orleans
Join Aitia at the GAP-Net Site Optimization Conference in New Orleans, Louisiana on Feb 28 – March 1, 2024. This conference is exclusively focused on enhancing clinical trials, bringing together clinical research leaders and executive teams from prominent Alzheimer’s and Parkinson’s disease clinical trial sites across North America, along with pharmaceutical sponsors, CROs, and other […]
Prediction of HD-related clinical outcome progression and imaging markers using AI-based Digital Twins to be Presented at HDTC 2024
We are delighted to announce that Aitia will be at the upcoming 19th Annual Huntington’s Disease Therapeutics Conference being held from February 26-29 in Palm Springs, California. We will be presenting a poster focused on identification of gene pathways with direct causal relationships to Huntington’s Disease (HD) through Gemini Digital Twins of HD patients, based […]
Causal AI to learn “Gemini Digital Twins” for Drug Discovery and Clinical Development: Join our CMO, Bruce Church at AIRIS 2024
We are excited to announce that Aitia will be participating at the AI Regulatory & International Symposium 2024 conference in Seoul, Korea. Our Chief Mathematics Officer, Bruce Church, will be taking the stage in the New Medical Products and Treatment Opportunities Using AI session to talk about Aitia’s commitment in accelerating AI-driven discoveries and share […]
Meet us at WSJ Health Forum
Join our CEO, Colin Hill with an influential community of scientists, business leaders, investors, policymakers and experts from across the sector to explore the trends, technologies, ideas and opportunities reshaping the business and science of health on Feb 21, 2024 in Boston at WSJ Forum. Find more details here.
Unveiling the AI Dominance in Biopharma: STAT Post JPM Conference Insights
JPM conference has echoed discussions about AI across the biopharmaceutical landscape. Catch up on key insights shared in the latest STAT article titled: “At Health Care’s Biggest Investor Conference, AI’s High Hopes Collided with Skepticism.” Sanofi’s chief executive, Paul Hudson, revealed the widespread integration of AI within the company: “More than 11,000 people across the […]
Servier Will Apply Aitia’s Gemini Digital Twins to Parkinson’s Drug
Spotlight on our joint effort with Servier, strengthening our partnership by entering a new collaboration focused on neuroscience. The aim of this cooperation is to leverage Aitia’s Gemini Digital Twins to identify patients most likely to respond positively to Servier’s Leucine-Rich-Repeat-Kinase 2 inhibitor (LRRK2i) in development treatment for Parkinson’s disease. Read the full article on […]
Meet us at J.P.Morgan Healthcare Conference
As we prepare to wrap up another exciting year for Aitia, we’re eagerly looking forward to a bustling 2024. For now, we’re gearing up for the J.P. Morgan conference, where our CEO, Colin Hill and President, COO, Jean-Michel Gries will be in attendance. Be sure to connect with them and request a meeting through the […]
Partner of Choice: Aitia and Servier Revolutionize the Landscape of Pancreatic Cancer Treatment
Spotlight on our joint effort with Servier to advance the discovery and simulation of drugs for Pancreatic Cancer. This strategic partnership aims to delve into the intricate mechanisms of this complex disease, with the goal of expediting the development of innovative therapies for individuals affected by pancreatic cancer. Read what Servier had to say about […]
Charles River and Aitia Join Forces to Harness AI and Gemini Digital Twins in Advancing Neurodegenerative and Oncology Research
Charles River Laboratories has entered into an agreement granting Aitia access to its artificial intelligence-powered drug solution platform. The objective is to expedite the development of multiple therapy programs targeting neurodegenerative diseases and oncology. Read more on the recent collaboration between Charles River and Aitia, in Fierce Biotech article. Full article available here.
Hear What Colin Hill had to say to Sidley on AI Use in Drug Discovery
Stephen Abreu, Sidley partner, talks to our Colin Hill about how the use of AI is revolutionizing the biotech space. Colin explains how our ability to predict and understand the actions of biological systems has historically been limited because of the complexity of “genetic circuitry,” but AI has allowed us to develop a more quantitative […]